Chantix might not increase heart risk, review shows

Pfizer's smoking-cessation treatment Chantix might not increase the risk of heart attack and other serious heart conditions, as was reported in a 2011 study, according to a review that looked at data on 9,232 people treated for three months. Researcher Judith Prochaska said the first study was misleading because "findings were inflated, and they were just focusing on that relative risk." Only 0.63% of 5,431 individuals developed a serious heart problem.

View Full Article in:

Review finds Chantix may not raise heart risks - Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX